Amid the soaring demand for GLP-1 drugs used to treat diabetes and support weight loss, the U.S. Food and Drug Administration (FDA) has issued an urgent warning for consumers using Ozempic. The agency is urging users to carefully inspect their medication labels after discovering that hundreds of counterfeit Ozempic injections have entered circulation outside of the authorized U.S. supply chain.
The FDA alert follows confirmation from Novo Nordisk, the manufacturer of Ozempic and the weight loss drug Wegovy, that counterfeit 1-milligram Ozempic pens had infiltrated the U.S. market. In response, the FDA seized the identified fake products on April 9, 2025.
